image: Figure 4: GBMF treatment disrupts the mitotic spindle(s) of GB cells. U251 cells were exposed to 27.12 MHz RF EMF amplitude modulated at GB specific frequencies three hours daily for seven days. (A) Mitotic spindle visualization and quantification by two blinded, independent investigators revealed that AM RF EMF treated cells exhibit a higher number of mitotic spindle disruption events than control cells. (B) There were significantly more mitotic events (Questionable+Abnormal) among the GBMF treated cells (366.67% increase) compared to the SHAM untreated cells; 2-tail t-test p = 0.0016. Additionally, when using the strictest analysis of mitotic events (Abnormal only) there was a significantly greater number of events among the GBMF treated cells (640% increase) compared to the SHAM untreated cells; 2-tail t-test p = 0.0478. Representative images/data shown.
Credit: Copyright: © 2025 Jimenez et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
“Intrabuccal administration of amplitude-modulated 27.12 MHz radiofrequency electromagnetic fields (AM RF EMF) resulting in the systemic delivery of low and safe levels of AM RF EMF has shown activity in several forms of cancer.”
BUFFALO, NY – October 14, 2025 – A new research paper was published in Volume 16 of Oncotarget on October 13, 2025, titled “Treatment of glioblastoma with tumor-specific amplitude-modulated radiofrequency electromagnetic fields.”
The study, led by Hugo Jimenez from Wayne State University School of Medicine, Karmanos Cancer Institute, introduces a novel treatment approach for glioblastoma, an aggressive and often treatment-resistant brain cancer. The findings open a new potential path for patients who currently have limited therapeutic options.
The approach uses a device developed by TheraBionic that delivers extremely low levels of radiofrequency electromagnetic fields, tuned to frequencies associated with glioblastoma. In laboratory experiments, this therapy significantly slowed the growth of multiple glioblastoma cell lines. It was especially effective against tumor stem cells, which are known to resist standard treatments and drive cancer reappearance. Researchers also found that the treatment’s effects depend on a calcium channel in tumor cells known as Cav3.2 (CACNA1H). When this channel was blocked, the therapy lost its effectiveness, highlighting the channel’s essential role in how tumor cells respond to the signal.
The therapy also disrupted the process of cell division by interfering with the mitotic spindle, a structure critical for cell replication. This disruption was associated with changes in the expression of genes that regulate cell division, particularly those involved in the “Mitotic Roles of Polo-Like Kinase” pathway. These effects were specific to tumor-targeted frequencies, as non-matching signals had no measurable impact.
The study also includes data from two patients with difficult-to-treat brain tumors who received the therapy through compassionate use. One patient with recurrent glioblastoma showed signs of clinical and radiographic improvement after one month of treatment. Another patient with oligodendroglioma tolerated the therapy well and had stable disease during follow-up imaging. Neither patient experienced serious side effects, further supporting the safety of the therapy.
“There was evidence of clinical and radiological benefit in a 38-year-old patient with recurrent GB and evidence of safety and feasibility in a 47-year-old patient with oligodendroglioma.”
This is the first study to demonstrate that tumor-specific radiofrequency therapy can suppress both tumor growth and cancer stem cells in glioblastoma. Similar results had previously been observed in liver and breast cancers. These findings contribute to the growing body of evidence supporting a new class of systemic, non-toxic cancer therapies. Further clinical trials will be crucial to confirm these results and fully assess the potential of this approach for treating brain cancer.
DOI: https://doi.org/10.18632/oncotarget.28770
Correspondence to: Hugo Jimenez – hugo.jimenez@wayne.edu
Abstract video: https://www.youtube.com/watch?v=uxYnWcNKYfg
Keywords: cancer, amplitude-modulated radiofrequency electromagnetic fields, glioblastoma, TheraBionic, CACNA1H, Cav3.2
Click here to sign up for free Altmetric alerts about this article.
About Oncotarget:
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:
X
Facebook
YouTube
Instagram
LinkedIn
Pinterest
Spotify, and available wherever you listen to podcasts
Click here to subscribe to Oncotarget publication updates.
For media inquiries, please contact media@impactjournals.com.
Journal
Oncotarget
Method of Research
News article
Subject of Research
People
Article Title
Treatment of glioblastoma with tumor-specific amplitude-modulated radiofrequency electromagnetic fields
Article Publication Date
13-Oct-2025
COI Statement
Alexandre Barbault reports that he holds TheraBionic Inc. and TheraBionic GmbH stock and a patent European # 2139557 licensed to TheraBionic, a patent U.S. # 8.977.365 B2 licensed to TheraBionic, a patent Australian # 2008232041 licensed to TheraBionic, a patent Brazil # PI0810084-5 licensed to TheraBionic, a patent Canada # 2,682,322 licensed to TheraBionic, a patent China # ZL 200880009864.4 licensed to TheraBionic, a patent Macau # J/001431 licensed to TheraBionic, a patent Israel # 201099 licensed to TheraBionic, a patent Japan # 5435240 licensed to TheraBionic, a patent Korea # 10-1478582 licensed to TheraBionic, a patent Mexico # 318857 licensed to TheraBionic, a patent Russia # 2594824 licensed to TheraBionic, a patent Saudi Arabia # 3075 licensed to TheraBionic, a patent Singapore # 155671 licensed to TheraBionic, a patent South Africa # 2009/06700 licensed to TheraBionic, and a patent United Arab Emirates # P849/09 licensed to TheraBionic. Boris Pasche reports that he holds TheraBionic Inc. and TheraBionic GmbH stock, grants from NCI P30CA0121978, grants from Charles L. Spurr Professorship Funds, during the conduct of the study; In addition, Dr. Pasche has a patent Europe # 2139557 licensed to TheraBionic, a patent U.S. # 8.977.365 B2 licensed to TheraBionic, a patent Australia # 2008232041 licensed to TheraBionic, a patent Brazil # PI0810084-5 licensed to TheraBionic, a patent Canada # 2,682,322 licensed to TheraBionic, a patent China # ZL 200880009864.4 licensed to TheraBionic, a patent Macau # J/001431 licensed to TheraBionic, a patent Israel # 201099 licensed to TheraBionic, a patent Japan # 5435240 licensed to TheraBionic, a patent Korea # 10-1478582 licensed to TheraBionic, a patent Mexico # 318857 licensed to TheraBionic, a patent Russia # 2594824 licensed to TheraBionic, a patent Saudi Arabia # 3075 licensed to TheraBionic, a patent Singapore # 155671 licensed to TheraBionic, a patent South Africa # 2009/06700 licensed to TheraBionic, and a patent United Arab Emirates # P849/09 licensed to TheraBionic. All other authors report no conflict of interest(s).